Webinar
Sub Population Insights for Precision Medicine towards Regulatory and Commercial Success
calendar

August 12, 2020

Calendar
clock

11:00am - 12:00pm

GMT-04:00

Register

View all IQVIA events

Regulatory and commercial success of drug assets depend upon how well available data including mechanism of action, off-label uses, side-effects and subpopulation efficacy are analyzed and incorporated into the product strategy. Conducting such thorough analysis before committing funds into a trial can save sponsors more than a billion dollars as well as years of valuable time developing a drug. These analyses can be performed through the use of artificial intelligence (AI) and machine learning-driven platforms that identify sub-populations of patients in real world data as well as in clinical trial data for safety, efficacy and side-effects. When sponsors can find these populations and adapt the trial design accordingly, it can reduce the rate of trial failure, rescue a promising molecule for further development, and capture better primary and secondary endpoint data to support approval, asset valuations and payer reimbursements.

Joining this webinar you will:

  • Understand current payer, provider, regulatory and technology trends
  • Learn how sub-population analysis in trial design and precision medicine can add valuable insights across the development process
  • Hear case studies from Oncology and see how the results of sub-population analysis could help sponsors make important decisions about the future of a drug assets earlier
  • Find out various R&D and Commercial applications of sub-population analysis

 

KEY SPEAKERS

Michael Kleinrock

Sr. Dir., Research Development, IQVIA Institute for Human Data Science

Russel Reeve

Vice President, Head of Biostatistics & Decision Science, IQVIA 

Jeff Hodge

Vice President, Development Solutions, Oncology CoE, IQVIA 

Kal Chaudhuri

Principal, Subpopulation Optimization and Modeling Solutions, IQVIA

Contact Us